We endeavor to conduct a portfolio of Long COVID clinical trials within our Long COVID Treatment Trial (LoCITT) program, operated by Scripps Research in partnership with CareEvolution and funded by the Schmidt Initiative for Long COVID (SILC). This work is crucial given the global burden of Long COVID, with over 400 million individuals affected, several mechanisms involved in contributing to over 200 symptoms, and no FDA approved treatments.
Be part of groundbreaking Long COVID research from Scripps Research
“The fact that it is being looked at is huge. This condition is scary because there are so many symptoms and doctors don’t know what to expect, so collecting this data is so important because it has the potential to be so impactful for so many people.”
Estela Mata
Long COVID user tester
By the Numbers
It is estimated that Long COVID affects at least 5% of adults in the United States and 400 million worldwide.
About LoCITT
The Long COVID research program at Scripps has:
- Remote participation options
- Participants in all 50 states
- Real-world data collected via digital health tools
Current Studies
Join the Long COVID Treatment Trial (LoCITT) waitlist
We are beginning a waitlist of people who are interested in participating to contribute to the advancement of Long COVID and infection-associated chronic conditions research.
You can sign up to receive updates on our Long COVID clinical trials and be notified before a clinical trial launches.
You can be removed from the waitlist by:
- Contacting the research team at longcovid@scripps.edu
- You will no longer be contacted about new research opportunities
Contact Us
For questions regarding this program, please contact us by email at longcovid@scripps.edu.
